Despite significant improvements to access to COVID-19 vaccine products, countries may not be able to access all required doses through a single product. COVID-19 vaccines available have different characteristics. Intentional planning of the portfolio of COVID-19 vaccine products is essential to the success of a country’s achievement of time-bound targets and goals. This live session will offer Ministries of Health and NITAGs practical tools, considerations and recommendations in their COVID-19 vaccine product choices to optimize their portfolio. Register now.